Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 7/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.30 |
| ▸ | CDK2 | P24941 | 2/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20674216 | 0.84 | BRD4 (0.41) | KAT2BBAZ2BBRD4GAAHTT | |
| SCHEMBL21959626 | 0.82 | PARP1 (0.33) | HTTCCNA2CDK2CCNA1 | |
| SCHEMBL20673851 | 0.81 | TSHR (0.39) | BRD4GAACCNA2CDK2CCNA1 | |
| SCHEMBL20631710 | 0.81 | KAT2B (0.41) | KAT2BBAZ2BBRD4GAACNR2 | |
| SCHEMBL20674214 | 0.71 | CCNA2 (0.38) | CCNA2CDK2CCNA1CNR2 | |
| SCHEMBL23937833 | 0.70 | MAPK1 (0.33) | HTT | |
| SCHEMBL23937834 | 0.69 | — | — | |
| SCHEMBL23937835 | 0.69 | KAT2B (0.38) | KAT2BBAZ2BBRD4GAA | |
| SCHEMBL23937642 | 0.66 | BRD4 (0.44) | BRD4GAACCNA2CDK2CCNA1 | |
| SCHEMBL20674093 | 0.66 | BRD4 (0.44) | BRD4CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | KAT2B 2578/4885BAZ2B 681/4885BRD4 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.